Back to Journals » Drug Design, Development and Therapy » Volume 11
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Decitabine reverses TGF-β1-induced epithelial–mesenchymal transition in non-small-cell lung cancer by regulating miR-200/ZEB axis [Corrigendum]
Zhang N, Liu Y, Wang Y, Zhao M, Tu L, Luo F. Drug Des Devel Ther. 2017;11:969–983.
Throughout the paper, including Figures, an abbreviation has been defined incorrectly. TGF-β1 was incorrectly defined ‘tumor growth factor-beta 1’. The correct definition for TGF-β1 is ‘transforming growth factor-beta 1’.
Read the original article
© 2017 The Author(s). This work is published and licensed by Dove Medical Press Limited. The
full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution
- Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted
without any further permission from Dove Medical Press Limited, provided the work is properly
attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.